SWITCHED ONcology is a global faculty of experts working together to improve the way cancer care is delivered around the world. With an extensive breadth of oncology experience, and a reputable ...

Pearlcatchers was set up in 2002 to offer a fresh approach to learning, development, teambuilding and events. Having experienced training, change and teambuilding events both internally and through ...

We are 20:20 Selection. Over more than 10 years we have built our reputation in providing unrivalled professional medical recruitment services to both our clients and candidates. During that time we ...

Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of ...